Lexicon Pharmaceuticals, Inc. (LXRX) Shares Sold by Quantitative Systematic Strategies LLC

Quantitative Systematic Strategies LLC trimmed its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 74.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,346 shares of the biopharmaceutical company’s stock after selling 36,550 shares during the quarter. Quantitative Systematic Strategies LLC’s holdings in Lexicon Pharmaceuticals were worth $69,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Pegasus Asset Management Inc. purchased a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at about $66,000. Paloma Partners Management Co purchased a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at about $73,000. D.A. Davidson & CO. purchased a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at about $87,000. CWM Advisors LLC raised its position in shares of Lexicon Pharmaceuticals by 30.2% during the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 3,030 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of Lexicon Pharmaceuticals by 409.3% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 11,862 shares in the last quarter. Hedge funds and other institutional investors own 99.16% of the company’s stock.

Lexicon Pharmaceuticals stock opened at $5.58 on Friday. Lexicon Pharmaceuticals, Inc. has a 1-year low of $4.25 and a 1-year high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 192.53% and a negative return on equity of 911.43%. The company had revenue of $17.10 million for the quarter, compared to analyst estimates of $13.33 million. During the same period in the prior year, the company posted ($0.27) EPS. The firm’s revenue for the quarter was down 49.7% on a year-over-year basis. As a group, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.59 EPS for the current year.

Several analysts have recently issued reports on the stock. BidaskClub cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Gabelli upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, March 25th. Stifel Nicolaus decreased their target price on shares of Lexicon Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, March 25th. Finally, Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 25th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $17.13.

TRADEMARK VIOLATION WARNING: “Lexicon Pharmaceuticals, Inc. (LXRX) Shares Sold by Quantitative Systematic Strategies LLC” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/21/lexicon-pharmaceuticals-inc-lxrx-shares-sold-by-quantitative-systematic-strategies-llc.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: Rule of 72

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.